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Background: The viral regulatory protein Tat is essential for establishing a productive transcription from the 5′-LTR
promoter during the early phase of viral gene expression. Formation of the Tat-encoding mRNAs requires splicing
at the viral 3′ss A3, which has previously been shown to be both negatively and positively regulated by the
downstream splicing regulatory elements (SREs) ESS2p and ESE2/ESS2. However, using the novel RESCUE-type
computational HEXplorer algorithm, we were recently able to identify another splicing enhancer (ESE5807-5838,
henceforth referred to as ESEtat) located between ESS2p and ESE2/ESS2. Here we show that ESEtat has a great
impact on viral tat-mRNA splicing and that it is fundamental for regulated 3′ss A3 usage.
Results: Mutational inactivation or locked nucleic acid (LNA)-directed masking of the ESEtat sequence in the context
of a replication-competent virus was associated with a failure (i) to activate viral 3′ss A3 and (ii) to accumulate
Tat-encoding mRNA species. Consequently, due to insufficient amounts of Tat protein efficient viral replication was
drastically impaired. RNA in vitro binding assays revealed SRSF2 and SRSF6 as candidate splicing factors acting
through ESEtat and ESE2 for 3′ss A3 activation. This notion was supported by coexpression experiments, in which
wild-type, but not ESEtat-negative provirus responded to higher levels of SRSF2 and SRSF6 proteins with higher
levels of tat-mRNA splicing. Remarkably, we could also find that SRSF6 overexpression established an antiviral state
within provirus-transfected cells, efficiently blocking virus particle production. For the anti-HIV-1 activity the
arginine-serine (RS)-rich domain of the splicing factor was dispensable.
Conclusions: Based on our results, we propose that splicing at 3′ss A3 is dependent on binding of the enhancing
SR proteins SRSF2 and SRSF6 to the ESEtat and ESE2 sequence. Mutational inactivation or interference specifically
with ESEtat activity by LNA-directed masking seem to account for an early stage defect in viral gene expression,
probably by cutting off the supply line of Tat that HIV needs to efficiently transcribe its genome.
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After integration of the human immunodeficiency virus
type 1 (HIV-1) into the host genome, the cellular RNA
polymerase II (RNAPII) transcribes just one primary
RNA from the 5′-long terminal repeat (5′-LTR). This
pre-mRNA preserves the open reading frames (ORFs)
for all of 18 different viral proteins altogether driving
replication, infectivity and immune evasion [1-5]. CAP-* Correspondence: schaal@uni-duesseldorf.de
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poses the gag/pol reading frames by virtue of their pro-
ximity to the 5′ end of unspliced RNAs to be the first
ones efficiently recognized by the scanning 43S riboso-
mal subunit. However, expression of seven other CAP-
distal ORFs including Tat and Rev is indispensable for
efficient viral replication. That is why a substantial
amount of the primary RNA – approximately half – is
diverted into the splicing pathway. Alternative splice site
selection allows the excision of upstream sequences con-
taining translational inhibitory AUGs and converts CAP-
distal reading frames to CAP-proximal ones efficiently
translated by the scanning ribosome.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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mRNAs is processed within an infected host cell, which
can be arranged by size into three major subgroups:
intronless 2 kb, intron-containing 4 kb and unspliced
9 kb RNAs [6]. Among the peculiarities of viral mRNA
splicing is that it constitutes a temporal gene expression
profile [7,8]. Early phase of viral gene expression is char-
acterized by the appearance of intronless 2 kb mRNAs,
including Tat- and Rev-encoding transcripts. Entry into
late phase of viral gene expression coincides with accu-
mulation of Rev protein, permitting the export of
intron-containing 4 kb and unspliced 9 kb mRNAs into
the cytoplasm ([9], for a recent review see [10]). These
would normally be retained within the cell’s nucleus, but
achieve export from the nucleus via the CRM1 pathway
requiring interactions between Rev and the Rev-
responsive element (RRE) within the env-coding se-
quence. During the late phase of viral gene expression,
the accessory and structural proteins Vif, Vpr, Vpu, and
Env are translated from the respective intron-containing
viral mRNAs (4 kb). Moreover, unspliced viral mRNA
(9 kb) is translated into structural and enzymatic pro-
teins or packed as genomic RNA into progeny virions.
Multiple splice sites (ss) and neighboring splicing regu-
latory elements (SREs) present within the HIV-1 genome
synergistically establish the considerable mRNA diversity
(Figure 1) (for a review see [11]). Expression of each of the
seven downstream ORFs is coupled to the extent of use of
a specific 3′ss found in its upstream region. Splice site
selection in turn is controlled by the activities of SREs in
the vicinity, which can act as “on” or “off” switches for the
assembly of a functional spliceosome at a given splice site,
and many viral SREs have already been identified in the
past (e.g. [12,13]). The identification of putative SREs has
been greatly facilitated by a computational algorithm: the
HEXplorer score HZEI of any given nucleotide in a specific
genomic sequence depends on a symmetric neighborhood
of 11 up- and downstream nucleotides. Using a RESCUE-
type algorithm, HZEI is calculated as average hexamer
Z-score in this neighborhood, based on hexamer over-
abundance in datasets of exonic compared to intronic
sequences flanking constitutive human 5′ splice sites.
Plotted along genomic sequences, HEXplorer score profiles
reflect splice enhancing (HZEI > 0) or silencing (HZEI < 0)
properties of sequence regions. For any mutation in the
vicinity of a 5′ splice site, its HEXplorer score difference
ΔHZEI between wild type and mutant sequences quantita-
tively measures the change in splice enhancing property
and correlates with 5′ splice site usage [14]. Using this
HEXplorer score, we were recently able to computation-
ally identify and experimentally confirm five novel SREs
being part of the viral SRE landscape [14].
In this work, we investigated the functional impor-
tance of one of these computationally identified SREs forviral replication: ESE5807-5838 appears to control acti-
vation of the Tat-specific 3′ss A3 and is henceforth re-
ferred to as ESEtat. Productive transcription from the
viral 5′-LTR heavily relies on the expression of viral Tat
protein, which facilitates transcriptional elongation by
recruiting the cellular transcriptional elongation factor
P-TEFb to RNAP II (for a recent review see [10]). Here
we show that ESEtat is critical for the formation of Tat-
encoding mRNAs within provirus-transfected HEK293T
cells and virus-infected Jurkat T-cells. ESEtat is bound by
the SR protein SRSF2, while SRSF6 binds mainly to
ESE2. We provide evidence that viral replication requires
an intact ESEtat, since mutational inactivation of the en-
hancer or locked nucleic acid-mediated masking leads to
a severe defect in virus particle production, which is
consistent with the defect in Tat-mRNA splicing. Not-
ably, we also show in this study that overexpression of
SRSF6 efficiently blocks the virus′ ability to replicate
and that the arginine-serine (RS) rich domain is dispens-
able for this antiviral activity.
Results
The ESEtat enhancer activity downstream of viral 3′ss A3 is
necessary for tat-mRNA splicing in provirus-transfected
cells
By applying the HEXplorer algorithm to all HIV-1 exons
in order to identify splicing enhancer activities, we loca-
lized a sequence downstream of the Tat-specific 3′ss A3
with splice enhancing properties, ESEtat (originally
termed ESE5807-5838) [14]. Since ESEtat lies upstream of
the previously published splicing regulatory elements
ESE2 and ESS2 [15] (Figure 1), we wished to analyze its
role in HIV-1 pre-mRNA splicing. To this end we per-
formed a mutational analysis and transfected HEK293T
cells with pNL4-3 (GenBank Accession No. M19921) or
mutant recombinant clones. The ESEtat nucleotide sub-
stitutions were selected by the HEXplorer algorithm to
maximally disrupt ESEtat enhancing property but not the
ESE2 (Figure 1B, [14]). The ESE2 mutations (Figure 1B)
were selected from [15]. To monitor equal transfection
efficiencies cells were cotransfected with a plasmid ex-
pressing the human growth hormone 1 (GH1). Following
transfection, the HIV-1 splicing pattern was determined
by semi-quantitative RT-PCR using primer pairs detecting
intronless or intron-containing HIV-1 mRNA classes (for
relative positions of the primers see Figure 1). In agree-
ment with earlier studies [6,12], the expression of viral
tat-mRNAs relative to viral nef- or env-mRNAs was rather
low (Figure 2A upper right, cf. Tat1 and Nef2 or lower
right, Tat5 and Env1). However, for in-depth analysis of
differences in the tat-mRNA expression profiles of the
NL4-3 variants, we additionally used the primer pair
E1/E4 exclusively detecting splicing events at 3′ss A1 to
A3 across the 5′-half of the viral pre-mRNA. Here we
Figure 1 Splicing regulatory elements (SREs) in the HIV-1 genome and mutational analysis of ESEtat. (A) Top: The open reading frames
(ORFs) are indicated by open boxes. The long terminal repeats (LTR) are located at both ends of the provirus. Center: All HIV-1 proteins are
encoded in a single primary transcript. More than 40 different viral mRNAs are produced by alternative splicing allowing efficient translation of all
ORFs within the infected cell. Intrinsic strength of the 5′ss (D1 to D4) and 3′ss (A1-A7) is indicated in parentheses (5′ss: HBond Score, http://www.
uni-duesseldorf.de/rna; 3′ss: MaxEntScore, http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq_acc.html). Bottom: Positions of the SREs
within the HIV-1 pre-mRNA: splicing enhancers (green) and silencers (red) are indicated. [ESE705-29 [14,40]; ESE-Vif [41]; ESEM [39]; ESE4932-62 [14];
ESE5005-32 [14]; guanosine (G) rich silencer G4 [41]; GI2-1 [42]; ESSV [43-45]; ESEvpr [12]; GI3-2 [16]; ESS2p [46]; ESE2 [15,47]; ESS2 [48-50]; guanosine-
adenosine rich (GAR) ESE [13,37,51]; E42 fragment [51]; ISS [52]; ESE3 [53]; ESS3 [53-55] (adapted to [51,56]). Primers used in RT-PCR analyses are
indicated by arrows (forward: E1, reverse: E4, E5, I4 and E7). (B) Top: HIV-1 exon 4 reference (pNL4-3) and mutant sequences used in this study.
The ESEtat is indicated by a grey rectangle. Previously published SREs in this region are underlined. Bottom: HEXplorer score profiles for wild-type
HIV-1 exon 4 reference (white) and mutant sequences (black). ESEtat is indicated by a grey rectangle. ESE2 is indicated by curly braces. Positions
of mutated nucleotides are indicated by arrows.
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among all tat-mRNA species (Figure 2A upper left, cf.
Tat1 and Tat2), which is again consistent with previousresults [6,12]. As expected from the computational predic-
tion, tat-mRNA levels were clearly decreased in the pres-




Figure 2 (See legend on next page.)
Erkelenz et al. Retrovirology  (2015) 12:29 Page 4 of 19
(See figure on previous page.)
Figure 2 ESEtat is required for activation of Tat-specific 3′ss A3. (A) 2.5 × 105 HEK293T cells were transiently transfected with each of the
proviral plasmids. 48 h post transfection, total RNA was isolated from the cells and analyzed by RT-PCR using different sets of primer pairs (primer
positions are shown in Figure 1A). HIV-1 mRNA species are indicated to the right of the gel images according to the nomenclature published
previously [6]. (B) Real-time PCR assays to specifically quantitate the relative levels of tat-mRNAs (top) and all viral mRNAs (bottom). For normalization
we monitored the total amount of cellular GAPDH present in every sample. Data represent expression ratios relative to that of wild-type pNL4-3
(bar 1). Values and error bars show the average ± standard deviation of three independent transfection experiments. (C) Left: Northern blot analysis
of total RNA isolated from the same RNA preparation as in (A). A hybridization probe was used specifically detecting HIV-1 exon 7. Right: Quantification
of Northern blot using RNAs from three independently performed transfection experiments. Data represent expression ratios relative to that of
wild-type pNL4-3 (bar 1), which was set to 1. For normalization the ribosomal RNA amount of each sample was calculated. Values and error bars show
the average ± standard deviation of three independent transfection experiments. (D) Western blot analysis of viral Gag and Tat expressed by wild-type
reference and mutant provirus. Supernatants and lysates were probed with a primary antibody against HIV-1 p24gag or HIV-1 tat. Equal amounts of
cell lysates were controlled by the detection of α-actin. (E) 2.5 × 105 HEK293T cells were transfected with 1 μg of proviral plasmids and 0.5 μg of
pcDNA3.1(+) or SVctat expressing viral Tat protein from a cDNA. Western blot analysis was performed as described in (D).
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vity is necessary for activation of 3′ss A3. Furthermore,
we repeatedly observed that reduced usage of one viral
3′ss led to activation of another [12]. Accordingly, it was
found that less usage of 3′ss A3 caused higher levels of
3′ss A2 activation (Figure 2A upper left, e.g. Tat1 and Vpr
cf. lane 1 and 2). However, the ESE2 mutation did not re-
duce but rather further increased tat-mRNA splicing effi-
ciency (Figure 2A lower right, e.g. Tat5 cf. lanes 1 and 3).
Although contrary to previous results [15], this finding
was in agreement with the HEXplorer-based prediction,
anticipating that the two inserted ESE2 point-mutations
would increase rather than decrease the enhancing prop-
erty of this sequence (Figure 1B). Finally, the ESEtat/ESE2
double-mutation (dm, Figure 2A upper left, lane 4)
showed an intermediate tat-mRNA splicing phenotype
compared to the respective single-mutations (cf. lanes 2
and 3 with lane 4).
Quantitative real-time PCR analyses confirmed a
failure of the ESEtat mutation to properly activate 3′ss
A3, as indicated by an approximately 10-fold reduction
in the levels of tat-mRNA (Figure 2B upper, Tat1, cf.
pNL4-3 and ESEtat (mut)). By contrast, the ESE2 mu-
tation showed an almost 8-fold upregulation in the
amount of tat-mRNA relative to wild-type (Figure 2B
upper, Tat1, cf. pNL4-3 and ESE2 (mut)). As expected
from insufficient amounts of Tat protein, which is
needed for transactivation of the HIV-1 promoter, the
ESEtat mutation caused an approx. 10-fold decrease in
viral RNA levels (Figure 2B lower, cf. pNL4-3 and ESEtat
(mut)). However, the ESE2 mutation showed an approx.
3-fold increase in RNA abundance (Figure 2B lower, cf.
pNL4-3 and ESE2 (mut)), as it was anticipated by the
higher levels of Tat-encoding viral mRNAs detected
within the quantitative and semi-quantitative RT-PCR
analyses. Finally, Northern blot analyses again confirmed
the overall decreased and increased amounts of viral
RNAs due to the ESEtat and ESE2 mutations, respectively
(Figure 2C, cf. lanes 2 – 5). Interestingly, we could detect
an increased expression of spliced versus unspliced viralRNAs for the ESE2 mutant, probably because of an aber-
rantly high A3 splice site activation (Figure 2C, cf. lanes
2 – 4).
In Western blot analyses, inactivating the ESEtat could
also be demonstrated to impair virus particle produc-
tion, as p24gag levels were nearly undetectable in the
supernatant of transfected cells (Figure 2D upper panel,
cf. lanes 2 and 3). However, to substantiate our finding
that mutation of the ESEtat results in a failure to provide
sufficient amounts of Tat protein needed to drive produc-
tive viral transcription, we wanted to examine whether
splicing-independent Tat coexpression from a cDNA may
rescue the ESEtat mutation causing the replication de-
fective phenotype. Indeed, co-transfection of HEK293T
cells with pNL4-3 ESEtat mutant and a Tat expression
plasmid at least partially restored virus particle production
(Figure 2E, cf. lanes 2 and 5) reinforcing the hypothesis
that shortage in the accumulation of Tat protein is
the major cause for the virus′ failure to successfully
propagate.
ESEtat is critical for activation of the Tat-specific 3′ss A3 in
the context of infected T-cells
To extend our analyses, Jurkat T-cells were infected with
equal amounts of p24 collected from the supernatants of
either wild-type- or mutant provirus-transfected HEK293T
cells. In agreement with the results obtained from the
transfection experiments, tat-mRNA levels detected by
RT-PCR were substantially down- or upregulated depen-
dent on whether cells were infected with ESEtat - or ESE2-
mutated virus (Figure 3A upper right, e.g. Tat1, for ESEtat
cf. lanes 1 and 2 and for ESE2 (mut) cf. lanes 1 and 3).
HIV-1 carrying both mutations produced tat-mRNAs at
levels between those found for the respective single mu-
tants (Figure 3A upper left, Tat1, cf. lanes 2-4). Herein, it
was once again found that the absence of the ESEtat activity
could not be entirely counterbalanced by an increased
ESE2 activity, since tat-mRNA splicing clearly failed to
reach wild-type levels (Figure 3A, upper left, Tat1, cf. lanes
1 and 4).
AB C
Figure 3 ESEtat-negative virus fails to efficiently replicate in
T-cells. (A) RT-PCR analysis of viral mRNAs taken from Jurkat T-cells
that were infected with 10 ng p24gag of wild-type or mutant NL4-3
virus. Total RNA was isolated 6 days post infection and subjected to
RT-PCR analysis using different sets of primer pairs (primer positions
are shown in Figure 1A). (B) Northern blot analysis of RNAs isolated
in (A) using a DIG-labeled HIV-1 exon7 probe detecting all three viral
mRNA species. (C)Western blot analysis of intracellular and supernatant
HIV-1 Gag collected 6 days post infection as described above. Actin
detection was used as loading control.
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protein for efficient viral transcription was recapitulated
by a strong decrease of all viral RNAs detected in the
Northern blot analysis (Figure 3B, cf. lanes 1 and 2).
However, contrary to what was seen in the context of
provirus-transfected HEK293T cells, the ESE2 mutant
showed no evidence for an increased transcriptionalactivity in the Northern blot analyses, which might be
due to a transfection-dependent higher responsiveness
of the viral LTR promoter to ectopically expressed Tat
(Figure 3B, cf. lanes 1 and 3). However, as a general ten-
dency for the ESE2 mutant, we could once again observe
a shift from unspliced to spliced viral RNAs hinting at
higher A3 splice site activation.
Overall, the results obtained from the Northern blot
analyses indicate that the maintenance of a balanced 3′
ss A3 activation by ESEtat is important for the virus’
competence to efficiently replicate. Hence, virus replica-
tion is impaired regardless of whether 3′ss A3 usage is
strongly decreased (due to a lack of Tat) or increased
(due to a lack of unspliced RNA) (Figure 3C, cf. lanes
1 – 3).
Masking ESEtat phenotypically mimics its mutational
inactivation
Recently, we could inactivate the intronic HIV-1 splicing
regulatory element GI3-2 located in intron 3 by co-
transfecting HeLa cells with a locked nucleic acid (LNA)
targeting the GI3-2 sequence [16]. To investigate whether
we could also mask the exonic ESEtat by rendering the se-
quence inaccessible for splicing factor binding as pre-
viously demonstrated by in vitro binding assays [16], we
cotransfected HeLa cells with the proviral pNL4-3 plasmid
and either an LNA directed against the ESEtat sequence,
the overlapping ESE2/ESS2 sequence or a randomized se-
quence as control (Figure 4A). In good agreement with
the results obtained from the mutational analyses (cf.
Figure 2), an LNA directed against the ESEtat sequence
led to a substantial reduction in the levels of Tat-encoding
mRNA species detected (Figure 4B left panel, e.g. Tat1 cf.
lanes 1 and 2), indicating a specific inhibition of the ESEtat
activity by sequence-directed LNA-delivery. By contrast,
an LNA targeting the ESE2/ESS2 sequence revealed a shift
towards Tat-encoding mRNA species (Figure 4B left panel,
e.g. Vpr and Tat1 cf. lanes 1 and 3) comparable to the in-
creased 3′ss A3 usage seen for the ESE2 mutant. However,
since masking the ESE2/ESS2 sequence resulted in an
even greater extent of 3′ss A3 activation (cf. Figure 2B),
these results might indicate a dominant role for the
negative acting ESS2 amongst both overlapping elements.
As it was expected, a randomized control-oligonucleotide
showed no impact on the viral splicing profile (Figure 4B
left panel, e.g. Tat1 cf. lanes 1 and 4). Revisiting mutational
inactivation of ESEtat, masking of the splicing enhancer se-
quence also led to reduced levels of viral mRNAs detected
by Northern blot (Figure 4C, cf. lanes 1 and 2), while RNA
levels of virus treated with the control-LNA were un-
affected (Figure 4C, cf. lanes 1 and 4). Although the in-
crease in A3 splice site usage detected after treatment
with the ESE2/ESS2 LNA did not appear to be associated
with a considerably higher amount of total RNA, it again
AB
C D
Figure 4 LNA-mediated masking of ESEtat mimics the influence of the mutated ESEtat on the viral splicing pattern and viral particle
production. (A) Schematic illustration of the location of ESS2p, ESEtat, ESE2 and ESS2 as well as the binding site for the locked nucleic acids
(LNAs) directed against ESEtat and ESE2/ESS2 sequences. (B) RT-PCR analysis of viral mRNA classes. HeLa cells were transiently transfected with
pNL4-3 and either ESEtat-LNA, the ESE2/ESS2 LNA or a scrambled LNA. Total RNA was isolated 24 h post transfection and subjected to RT-PCR
analysis using different primer pairs (Figure 1A). (C) Northern blot analysis of total RNA collected in (B) using a DIG-labelled probe hybridizing to
HIV-1 exon 7. (D) Western blot analysis of cellular and supernatant viral Gag of co-transfected cells from (B). The detection of actin served as
loading control.
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RNAs (Figure 4C, cf. lanes 1 and 3).
As expected from a failure of ESEtat-LNA treated virus
to accumulate viral RNAs, addition of the ESEtat-specific
LNA also caused a reduction in virus particle production
(Figure 4D, cf. lanes 1 and 2). However, virus particle
production was also affected when virus was treated
with either the ESE2/ESS2- or the control-LNA, al-
though to a much lesser extent for the latter (Figure 4D,
cf. lanes 1, 3 and 4). Nevertheless, this finding suggests
an additional potentially sequence-unspecific antiviral ef-
fect by LNAs, which might address viral gene expression
at a step later than RNA processing and requires further
investigation.
The SR proteins SRSF2 and SRSF6 act through ESEtat and
ESE2 to activate 3′ss A3
Previous studies suggested that activation of 3′ss A3 can
be increased following coexpression of the SR protein
SRSF2 and SRSF5 [17-19]. Furthermore, footprinting
studies by Zahler et al. [15] indicated partial binding of
SRSF2 not only to ESE2, but also further upstream over-
lapping with the HEXplorer predicted ESEtat sequence.
However, we had some additional evidence that the SR
protein SRSF6 might also be involved in promoting usage
of 3′ss A3. Therefore, we revisited RNA precipitation ex-
periments upon immobilization of in vitro transcribed
RNAs containing the wild-type and mutant sequences to
identify SR proteins which in the presence of the hnRNP
A1 binding site ESS2 can bind to ESEtat or ESE2 or both
(Figure 5A). To control for equal precipitation efficiencies,
the 5′-end of each RNA substrate was endowed with a
single copy of an RNA stem loop, serving as binding site
for the bacteriophage MS2 coat protein added as recom-
binant protein to the nuclear extracts [20,21]. As ex-
pected, pull-down analyses revealed SRSF2 binding to the
wild-type sequence (Figure 5B, upper and middle panel,
lane 1). Mutating the HEXplorer predicted ESEtat enhan-
cer activity (Figure 1B, ESEtat (mut)) without altering the
previously mapped SRSF2 binding site [15], surprisingly
led to loss of SRSF2 binding, mapping an SRSF2 binding
site within ESEtat but upstream of ESE2 (Figure 5B, upper
and middle panel, cf. lanes 1 and 2). Moreover, in agree-
ment with the HEXplorer prediction (Figure 1B, ESE2
(mut) middle bar graph), levels of SRSF2 were even in-
creased when ESE2 was mutated (Figure 5B, upper and
middle panel, cf. lanes 1 and 3), suggesting that the under-
lying binding site is located within ESEtat. This was further
supported by undetectable amounts of SRSF2 on RNAs
with the ESEtat/ESE2 double mutation (dm) (Figure 5B,
upper and middle panel, cf. lanes 1 and 4). Notably, the
ESEtat point mutations not only disrupted binding of
SRSF2, but also binding of SRSF5 similarly described to
increase tat-mRNA splicing upon coexpression [17,19].Interestingly, SRSF6 binding was detected on wild-type
but not reduced on ESEtat negative RNAs (Figure 5B,
upper panel, cf. lanes 1 and 2). Instead, it was significantly
increased on both, ESE2 single and ESEtat/ESE2 double
mutant RNAs (Figure 5B, cf. lanes 1, 3 and 4), suggesting
that the underlying binding site for SRSF2 is located
within ESEtat, whereas the underlying binding site for
SRSF6 is within the ESE2 sequence. Furthermore, this
finding indicates that the ESE2 mutations generated a new
SRSF6 binding site or increased the affinity for an already
existing one.
Consistently, in coexpression experiments the ESEtat
mutant showed only a poor response to higher levels of
SRSF2 in comparison to the wild-type sequence (Figure 5C
middle and lower panel, Tat1, cf. lanes 1and 5 with lanes 2
and 6), indicating a substantial reduction in the binding
affinity of SRSF2 to the viral RNA. Surprisingly, the ESEtat
mutant also did not respond to SRSF6 upregulation
(Figure 5C middle and lower panel, Tat1, cf. lanes lanes 2
and 10), although pull-down assays demonstrated that
SRSF6 binding was not affected by the respective nucleo-
tide exchanges. Given this finding, it seems that either
SRSF6 is present already in saturating amounts or that
SRSF6 and SRSF2 cooperatively activate Tat-specific 3′ss
A3, either through two separate required mechanisms or
by stabilizing each other on their respective target se-
quences. Since, SRSF6 binding alone is not sufficient to
promote proper 3′ss A3 recognition (Figure 5C middle
and lower panel, Tat1, cf. lanes 2 and 10), a cooperative ef-
fect for the splicing machinery seems to be more likely.
In agreement with this hypothesis, and given increased
amounts of both bound SRSF2 and SRSF6 to the ESE2
mutant, tat-mRNA splicing was found to be markedly
upregulated in case of the respective proviral clone co-
expressed with either one of both SR proteins (Figure 5C
middle and lower panel, Tat1, cf. lanes 3, 7 and 11).
These results reinforced the conclusion that ESE2-affecting
nucleotide changes render the target sequence more sus-
ceptible for cooperative SRSF2 and SRSF6 binding.
Finally, the double-mutant failed to respond to SRSF2
coexpression with an increase in Tat-specific 3′ss A3 ac-
tivation (e.g. shift from Tat1 to Tat2 isoforms, Figure 5C
upper panel, cf. lanes 4 and 8), while tat1-mRNA spli-
cing could be increased in presence of higher levels of
SRSF6 (e.g. shift from Tat2 to Tat1 isoform, Figure 5C
upper panel, cf. lanes 4and 12). Therefore, higher local
SRSF6 concentrations appear to allow promoting 3′ss
A3 activation even in presence of the ESEtat mutations,
possibly by either stabilizing the weaker affinity of SRSF2
for the ESEtat mutant sequence or by showing a higher
potency to remove competing hnRNPA/B proteins from
the ESS2 sequence, which were proposed to inhibit spli-
cing of the upstream intron by directly masking the






Figure 5 (See legend on next page.)
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Figure 5 The SR proteins SRSF2 and SRSF6 bind downstream of 3′ss A3 to control tat-mRNA splicing. (A) In vitro-transcribed RNA substrates
used for the RNA pull-down assays. Mutated nucleotides are indicated below the wild-type reference (pNL4-3) at corresponding positions and “-“ denotes
wild type nucleotide. (B) RNAs were immobilized on Agarose beads and analyzed for the presence of SR proteins with specific antibodies directed
against SRSF2 (Abcam, ab28428) or phosphorylated SR proteins (Invitrogen, 1H4G7). Recombinant MS2 coat protein was added to HeLa cell nuclear
extracts and served as a control for equal precipitation efficiencies. (C) 2.5 × 105 HEK293T were transfected with pNL4-3 or mutant provirus and
pcDNA3.1(+), an SRSF2 or SRSF6-expressing plasmid. 48 h after transfection RNAs were analyzed by RT-PCR (C) or Northern blot (D). (E) Cell lysates and
supernatants from transfected HEK293T cells were analyzed for Gag expression as described before (see Figure 2). (F) Left: Cell lysates and supernatants
from HEK293T cells cotransfected with pNL4-3 and gradually increasing amounts of SRSF6 expressing plasmid that were analyzed for Gag expression as
described before. Right: Serial dilutions of cell lysates and supernatants from transfected HEK293T cells analyzed for Gag expression.
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was less pronounced for ESEtat/ESE2-double negative
virus than for the wild-type, which indicates that an
intact ESEtat is pivotal for higher 3′ss A3 activation
(Figure 5C lower panel, Tat1, cf. lanes 1 and 9 with 4
and 12).
Aside from alterations in tat-mRNA splicing following
SR protein coexpression, SRSF6 induced additional
changes within the viral splicing pattern. Accordingly, not
only did SRSF6 coexpression favor tat-mRNA splicing
(Figure 5C lower panel, Tat1, cf. lanes 1 and 9), but also
exclusion of exons 4cab and 5 from Rev- and Nef-
encoding mRNA species (Figure 5C lower panel, Rev1+2,
Nef2 and Nef1, cf. lanes 1 and 9), which was consistent
with an earlier study [22]. Thus, SRSF6 effects on viral
splicing include ESE2-dependent promotion of 3′ss A3
usage, but also prevention of exons 4cab and 5 inclusion
into rev- and nef-mRNAs through interference with the
viral GAR element [22] or another so far unknown
mechanism.
Next, we wished to determine the influence of SR pro-
tein coexpression on overall viral mRNA expression. It
is striking to notice that while SRSF2 coexpression did
not appear to significantly alter the levels of viral total
RNAs, these were instead clearly decreased in the pre-
sence of higher SRSF6 concentrations within the cells
(Figure 5D, cf. lanes 2, 6 and 10). This dramatic re-
duction in the overall levels of viral RNAs detected by
Northern blot analyses anticipated a strong reduction in
the levels of virus particles measured in the supernatant
of provirus-transfected HEK293T cells with elevated
SRSF6 concentrations. However, the reduction in Gag
expression and virus particle production seemed to be
less pronounced than expected from the Northern blot
analyses (Figure 5E, cf. lanes 2, 6 and 10), which might
be due to an increased Gag translational efficiency in
presence of higher levels of SRSF6 [23]. To expand our
analyses, and since the observed negative effect of SRSF6
on viral gene expression was in contrast to what was
found in an earlier study [22], we tested varying concentra-
tions of SRSF6 expression plasmid and could find that
these inhibitory activities could already be observed at a ra-
tio of 1:5 relative to transfected proviral plasmid (Figure 5F
left panel, cf. lanes 2 and 5). To exclude loading ofsaturating amounts of lysate and supernatant in Figure 5E,
we also measured Gag expression and virus particle pro-
duction for gradual sample dilutions, reinforcing a defect
in viral gene expression at higher levels of SRSF6 within
provirus-transfected HEK293T cells (Figure 5F, right
panel, cf. lanes 1-3 and 4-6).
Notably, among other tested splicing factors such as
SRSF1 or hnRNP H, SRSF6 overexpression had the
strongest negative effect on pNL4-3 gene expression
(data not shown). We therefore conclude that higher
levels of SRSF6 may predispose a target cell to a higher
degree of resistance against NL4-3 replication.
The arginine-serine (RS) rich splicing effector domain of
SRSF6 is not required for the global aberrations in viral
pre-mRNA splicing
Given the unexpected finding that SRSF6 efficiently
blocked virus particle production when coexpressed to-
gether with the infectious clone pNL4-3, we next wished
to analyze which protein domain accounts for this antiviral
activity. To this end, we generated different truncated
SRSF6 isoforms whose removed regions either included
only the arginine-rich (RS) domain (RRM1/H), the RS do-
main together with the RRMH domain (RRM1/L) or all
but the RRM domain (RRM1) (Figure 6A, left panel).
Proper expression of all variants was controlled by Western
blotting (Figure 6A, right panel). Finally HEK293T cells
were cotransfected with pNL4-3 and individually each of
these SRSF6-derived variants. Again, we could observe
that in the presence of higher levels of full-length SRSF6
splicing at 3′ss A3 was greatly increased (Figure 6B mid-
dle left (E1/E5), Tat1, cf. lanes 1 and 2). As a recurring
theme, SRSF6 coexpression not only led to a shift in the
viral splice acceptor selection from 3′ss A5 (e.g. Nef2 or
Env1) towards 3′ss A3 usage (Tat1 and Tat5), but also ap-
peared to repress inclusion of exons 4cab and 5 into viral
Rev and Nef-mRNAs (Figure 6B middle right (E1/E7),
Rev1+2 and Nef1, cf. lanes 1 and 2). Unexpectedly, dele-
tion of the RS domain, which is commonly described to
be the splicing effector domain of SR proteins, did not
relieve SRSF6-mediated global changes in viral splicing
(Figure 6B middle right (E1/E7), Tat1, Rev1+2 and Nef1,
cf. lanes 1 and 3). Additional deletion of the RRMH was
still not sufficient to reinduce the wild-type splicing
AB
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Figure 6 The arginine-serine (RS) rich C-terminus as well as the RRMH domain of SRSF6 are dispensable for its antiviral activity.
(A) SRSF6 protein variants used in the coexpression experiments. Proper expression of all truncated SRSF6 variants was confirmed using an
antibody specifically recognizing an HA epitope (Sigma-Aldrich, H6908), which was C-terminally fused to each mutant. HEK293T cells were
transiently cotransfected with 1 μg of pNL4-3 and 1 μg of pcDNA3.1(+) or the respective SRSF6 variant-expression plasmid. Samples from the
same RNA preparations were analyzed by both RT-PCR (B) and Northern blot (C). (D) Cellular lysates and supernatants were analyzed by Western
blot using antibodies directed against viral Gag or cellular actin (loading control). Values and error bars show the average ± standard deviation of
two independent transfection experiments.
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of 3′ss A3 splicing (Figure 6B middle left (E1/E5), Tat1, cf.
lanes 1 and 4). However, a shift back from exon 5-lacking
Nef1- to exons 4cab-including Rev1/2-mRNA and to exon
5-including Nef2-mRNA isoforms could be observed,
while increased accumulation of tat-mRNA species due to
higher 3′ss A3 activation was unaltered (Figure 6B middle
left (E1/E5), Nef1 Rev1+2 or Nef2, cf. lanes 3 and 4).
Given these findings, we argue that while the RRMH ap-
pears to be dispensable for 3′ss A3 activation, it appears
to be necessary for inhibition of exon 5 inclusion. Surpri-
singly, the RS domain seems to be entirely dispensable for
the ample changes within the viral pre-mRNA splicing
pattern that are conferred by SRSF6.
However, when additionally the linker region was de-
leted and only the RRM1 of SRSF6 was expressed in
pNL4-3-transfected HEK293T cells, no aberrantly in-
creased levels of tat-mRNA splicing could be detected
and hence, the viral splicing pattern was entirely un-
affected (Figure 6B middle right (E1/E7), Tat1, cf. lanes 1
and 5). On the basis of these results, we propose that
the SRSF6-mediated tat-mRNA oversplicing requires the
37 amino acid long linker region between RRM1 and
RRMH, while both the RS domain and RRMH are dis-
pensable. In contrast, inhibition of exons 4cab and 5 rec-
ognition by the spliceosome also requires RRMH.
The results obtained from Northern and Western blot
analyses were mostly consistent with the observed activ-
ities of all tested SRSF6 variants (Figure 6C-D). Thus, it
was found that coexpression of full-length SRSF6 led to
a strong decrease in the levels of all viral mRNAs
(Figure 6C, cf. lanes 1 and 2, ~ 5-fold) and consequently
also in the levels of p24gag proteins detected within the
cells and supernatant (Figure 6D, cf. lanes 1 and 2).
However, a total rescuing of virus RNA expression and
particle production could already be achieved when the
RRM1/L variant was coexpressed with proviral DNA
(Figure 6C-D, cf. lanes 1, 2, and 4), indicating that the
antiviral activity of SRSF6 is unrelated to the Tat over-
splicing phenotype. From these results we conclude that
the RRMH is a major contributor to the strong antiviral
activity elicited by higher SRSF6 concentrations.
The varying abilities of the different SRSF6 variants to
localize within the nucleus correlate with their antiviral
activity
Next, we wished to figure out to which extent the dif-
ferent activities of the SRSF6 variants might be due to
an altered subcellular localization. For this purpose, we
transfected HeLa cells with the HA-tagged SRSF6 va-
riants described above and analyzed the subcellular
localization of these proteins by confocal laser-scanning
microscopy. As expected, full length SRSF6 almost en-
tirely accumulated within the cellular nucleus (Figure 7B)in support of the notion that the antiviral activity of SRSF6
results from changes in nuclear processing of viral or cel-
lular mRNAs encoding for replication-relevant proteins.
However, unexpectedly, the RRM1/H variant predomin-
antly localized to the nucleus as well (Figure 7C) despite
deletion of its arginine-serine (RS) domain, which was
previously described to be important for nuclear targeting
of SR proteins [24-26]. However, the RRM1/L and RRM1
variants both deprived of their antiviral activity were
mostly found within the cytoplasm (Figure 7D and E).
This may imply that SRSF6 requires a RRMH domain-
dependent nuclear localization for inhibition of viral gene
expression, but does not exclude a direct contribution of
the RRMH domain to the SRSF6 mode of viral repression.
Discussion
In this study, we provide evidence for the functional im-
portance of a novel splicing enhancer – termed ESEtat –
as the dominant splicing regulatory element underlying
viral Tat protein expression. Mutational disruption of
this enhancer activity led to a severe defect in the forma-
tion of Tat-encoding viral mRNA species that strongly
impaired virus ability to replicate within infected cells.
Since LNA-directed masking of the ESEtat sequence was
also linked to a failure in the production of tat-mRNAs,
we can exclude accidental generation of a new, artificial
silencer by the inserted point-mutations.
Combining the results obtained from our RNA pull-
down assays and those from the splicing factor coex-
pression experiments, we suggest that the SR proteins
SRSF2 and SRSF6 act through ESEtat and ESE2 to
promote 3′ss A3 use. Both proteins are precipitated with
either lower or higher efficiencies on the respective mu-
tant RNAs (SRSF2: ESEtat; SRSF6: ESE2) than on the
wild-type RNAs and higher cellular levels of SRSF2 or
SRSF6 account for increased splicing of tat-mRNA spe-
cies for ESEtat virus but not ESEtat-negative virus. These
findings are in line with several preceding studies that
found a shift towards tat-mRNA species following up-
regulation of SRSF2 or SRSF6 [17-19,22,27]. We suggest
a model in which neither of these two SR proteins is
dispensable for splicing at 3′ss A3, but rather work
together for optimized tat-mRNA expression. In this
model, SRSF6 bound to the ESE2 sequence prevents
hnRNP A/B protein recruitment to the juxtaposed ESS2,
thereby stabilizing upstream SRSF2/ESEtat interactions
for activation of 3′ss A3 (Figure 8). Thus, even though
SRSF6 binding alone may not be sufficient to activate 3′
ss A3, SRSF6 still promotes a shift towards tat-mRNA
splicing in the context of an intact ESEtat when its spli-
cing effector domain (RS domain) has been removed.
Accordingly, SRSF2 seems to play a more direct and
SRSF6 a more indirect role for assembly of spliceosomal





Figure 7 The antiviral activity of the SRSF6 variants correlates with their subcellular localization. Subcellular localization of the HA-tagged
SRSF6 variants was unraveled by immunostaining of transiently transfected HeLa cells using an anti-HA and an anti-mouse Alexa Fluor® 488
antibody. Cell nuclei were stained with DAPI and glass slides were analyzed by confocal laser-scanning microscopy.
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suggest an SRSF2-equivalent role for SRSF5 in ESEtat
dependent enhancement of tat-mRNA splicing, which
needs to be clarified by upcoming studies.
Given the pivotal role of Tat for the onset of product-
ive viral transcription, we presume that ESEtat might be
a sensor for the cell type-specific intracellular concentra-
tions of SRSF2 and SRSF6. This is in agreement withprevious results, suggesting that the lower SRSF2 ex-
pression within macrophages relative to T-cells might be
the reason for suboptimal Tat expression and slower
virus replication kinetics [28]. Furthermore, we could
confirm our previous observation that stronger activa-
tion of one viral splice site caused weaker activation of
another within the viral 3′ss selection scheme [12]. Con-




Figure 8 Model for SRSF2 and SRSF6-mediated 3′ss activation. (A) SRSF6 and hnRNP A/B proteins compete for binding to their overlapping
binding sites located within ESE2 and ESS2. Depending on the SRSF6 binding efficiency (B), SRSF2 interacts with the upstream ESEtat and guides
spliceosomal components to 3′ss A3. (C) Inactivation of ESEtat is associated with a failure in efficient spliceosome recruitment irrespective of
higher SRSF6 binding (D).
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Tat-specific 3′ss A3 and e.g. Vpr-specific 3′ss A2.
Although the modus operandi governing mutually
exclusive-like splice site choice still remains unknown,
we think that local constraints in delivering sufficient
spliceosomal components for early splice site recogni-
tion might be causative for the observed competition
among viral splice sites (for a recent review see [29]).
In particular, we could find that the splicing factor
SRSF6 leads to an almost complete inhibition of viral
replication when overexpressed. This was unique to
SRSF6 since we could not find any comparable inhi-
bitory effect for any other splicing factor tested so far
(data not shown).
Revisiting the barrier functions of other human restric-
tion factors (such as APOBEC3G), higher SRSF6 con-
centrations appear to bring about a cellular state that is
incompatible with efficient HIV replication. Although
SRSF6 does not satisfy the criteria of a bona fide restric-
tion factor, at least it shares the salient feature of thisprotein family to dramatically impair the virus compe-
tence to successfully replicate. Given the high depen-
dence of HIV-1 (and other retroviruses) on regulated
alternative splicing, it seems plausible that splicing fac-
tors and their relative concentrations can be considered
as cellular restriction factors operating in a narrow range
for HIV-1 replication. A role of splicing factors in de-
fense of foreign or selfish nucleic acids is further sup-
ported by the finding that the splicing factor hnRNP C
was recently shown to protect transcriptome integrity
through selective repression of cryptic splice sites within
transposon-derived Alu elements [30]. It remains un-
clear by which mechanism SRSF6 inhibits HIV-1 gene
expression. Based on the finding that SRSF6 overexpres-
sion appears to repress splicing of the viral Rev-specific
exons 4cab, we first considered that the antiviral activity
might be a result of a failure to accumulate sufficient
levels of Rev protein, needed to drive the export of
intron-containing and unspliced viral mRNAs to the
cytoplasm ([9], for a recent review see [10]). However,
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proviral clone bypassing Rev dependency through use of
an alternative export element [31] seemed to partially
overcome the SRSF6-mediated antiviral activity, neither
of both was able to fully restore virus particle produc-
tion (data not shown), indicating additional superim-
posed negative effects on viral gene expression.
Notably, the arginine-serine (RS)-rich domain was
largely dispensable for the nuclear import, viral splicing
changes and the antiviral activity of SRSF6. This is sur-
prising, since RS domains are generally supposed to act
as nuclear localization signals (NLS) and to be funda-
mental for the transport of SR proteins into the nucleus
[24-26]. Moreover, they are considered to represent the
main protein effector domain of SR proteins [20,32-34].
This may indicate that the effects of SRSF6 on viral spli-
cing are rather based on displacement of other splicing
factors from overlapping binding motifs (for instance
hnRNPA/B to ESS2) [15].
However, despite an unquestioned requirement of the
RRMH domain for nuclear localization, it remains elu-
sive whether it is also directly relevant for the antiviral
activity of SRSF6. This uncertainty also applies to all
other protein regions (with exception of the RS domain).
Discriminating the respective contributions of the diffe-
rent SRSF6 domains to the establishment of the antiviral
state would have required equal nuclear import effi-
ciencies conferred by fusion of a heterologous NLS.
Therefore, it still awaits further studies e.g. to establish
whether RRMH is directly involved in inhibition of viral
gene expression or only directs efficient import of SRSF6
into the nucleus. In addition, it remains to be answered
whether the failure of the RRM1 variant to affect viral
mRNA splicing results from (i) inability to enter the nu-
cleus, (ii) importance of the linker region for viral RNA
substrate affinity as described for other RNA binding
proteins (e.g. [35,36]) or (iii) defective protein-protein
interactions. Despite some differences in data interpre-
tation, our results are consistent with earlier studies in-
dicating an SRSF6-associated shift within the splicing
pattern towards tat-mRNA species [22,27] as well as a
reduction in total levels of viral RNA [22,23,27]. How-
ever, in these studies primarily replication-incompetent
subgenomic HIV-1 plasmids have been assayed, which
might not necessarily reflect all SRSF6 coexpression-
related effects such as an enhancement of viral Gag ex-
pression [23].
Some cellular splicing factors show altered expression
levels during the course of an HIV-1 infection [28], en-
couraging the notion of splicing factors to act as barrier
proteins. We suggest that higher or lower levels of SRSF6
may predispose a cell to an increased or decreased HIV-1
resistance, and that it needs to be downregulated for effi-
cient viral replication. Therefore, profiling of splicingfactor expression in different target cells may help to pre-
dict the outcome of viral replication.
Conclusions
ESEtat contributes to the activation of 3′ss A3 for spli-
cing of viral tat-mRNAs. ESEtat-negative HIV-1 fails to
sufficiently accumulate tat-mRNAs, resulting in a short-
age of Tat trans-activator protein. Throughout coexpres-
sion experiments, we found evidence for an antiviral
activity of splicing factor SRSF6, demonstrated by an
almost complete loss of virus particle production. Inter-
estingly, the arginine-serine (RS)-rich effector domain
played no important role either for nuclear localization
or for the negative effect on HIV-1 gene expression.
Methods
Oligonucleotides
Oligonucleotides were obtained from Metabion GmbH
(Martinsried, Germany).
Primers used for site-directed mutagenesis (see Table 1
in separate file).
Primers used for semi-quantitative and quantitative
RT-PCR analyses (see Table 2 in separate file).
Primers used for RNA in vitro binding assays and se-
quences for locked nucleic acids (see Table 3 in separate
file).
Plasmids
Proviral HIV-1 exon 4 mutants were generated by PCR
mutagenesis. Therefore, the EcoRI/NdeI fragment of
SV-env [37] was first replaced by the EcoRI/NdeI frag-
ment of the proviral plasmid pNL4-3 (GenBank Acces-
sion No. M19921) to obtain preclone SV-env5743-8892.
Subsequently, the SalI/NdeI fragment was substituted
with PCR products using appropriate forward PCR pri-
mer (see Table 1) and #640 as a reverse PCR primer con-
taining SalI and NdeI restriction sites. Finally, proviral
HIV-1 variants were cloned by replacing the EcoRI/XhoI
fragment of a pNL4-3 subclone carrying an arbitrarily
choosen EcoRI/XhoI fragment of different length with
mutated SV-env5743-8892 fragments.
SRSF6 variants were cloned by replacing the XmaI/
BamHI fragment (for SRSF6-HA; RRM1/H-HA; RRM1/
L-HA) or the BbsI/BamHI fragment (for RRM1-HA) of
pCG-SRp55 (kindly provided by E. Buratti) with PCR
products using appropriate forward and reverse primers
(see Table 1). After cloning, all PCR amplicons were vali-
dated by sequencing.
pXGH5 [38] was cotransfected to monitor transfec-
tion efficiencies in quantitative and semi-quantitative
RT PCR analyses. The plasmid expresses the human
growth hormone 1 (hGH1) under control of the mouse
metallothionein-1 promoter.
Table 1 Primers used for cloning





#4709 5′ GGG TGT CGA CAT AGC AGA ATA
GGC GTT ACT CGA CAT AGG ATA




#4753 5′ GGG TGT CGA CAT AGC AGA ATA
GGC GTT ACT CGA CAG AGG AGA GCA
AGA AAT GGA GCC AAT CGA TCC TAG
ACT AGA GCC CTG G 3′
pNL4-3 ESEtat/
ESE2 (mut)
#4754 5′ GGT GTC GAC ATA GCA GAA TAG GCG
TTA CTC GAC ATA GGA TAG CAA AAA ATG
GAG CCA ATC GAT CCT AGA CTA
GAG CCC TGG 3′







#4836 5′ ATC GTA GAG CAC GCC CG 3′
pCG-RRM1-HA #4971 5′ TCC ATA GAA GAC ACC GGG ACC 3′
Reverse
pCG-SRSF6-HA #5085 5′ TCT CAG GAT CCT TAC GCG TAA
TCA GGA ACA TCG TAT GGG TAA
CCA CCA CCA CCA TCT CTG GAA
CTC GAC CTG G 3′
pCG-RRM1/H-HA #5084 5′ TCA GGA TCC TTA CGC GTA ATC
AGG AAC ATC GTA TGG GTA ACC
ACC ACC ACC TGG CTT ATC TTC
AAT AAG CCT AAT ATT TC 3′
pCG-RRM1/L-HA #5083 5′ TCT CAG GAT CCT TAC GCG TAA
TCA GGA ACA TCG TAT GGG TAA
CCA CCA CCA CCT TCT GTA CGA
ACA GGT GGT C 3′
pCG-RRM1-HA #5086 5′ TCT CAG GAT CCT TAC GCG TAA
TCA GGA ACA TCG TAT GGG TAA
CCA CCA CCA CCG CCC CGG GCG
TGC TCT A 3′
Table 2 Primers used for semi-quantitative and
quantitative RT-PCR
Target RNA Primer Sequence
Viral mRNA
classes
#1544 (E1) 5′ CTT GAA AGC GAA AGT AAA GC 3′
#3392 (E7) 5′ CGT CCC AGA TAA GTG CTA AGG 3′
#640 (I4) 5′ CAA TAC TAC TTC TTG TGG GTT GG 3′
#3632 (E4) 5′ TGG ATG CTT CCA GGG CTC 3′
#3637 (E5) 5′ GAG AAG CTT GAT GAG TCT GAC 3′
Tat1 #3631 5′ CGG CGA CTG AAT TGG GTG T 3′
#3632 5′ TGG ATG CTT CCA GGG CTC 3′
All viral RNAs #3387 5′ TTG CTC AAT GCC ACA GCC AT 3′
#3388 5′ TTT GAC CAC TTG CCA CCC AT 3′
GAPDH #5163 5′ CCA CTC CTC CAC CTT TGA 3′
#5164 5′ ACC CTG TTG CTG TAG CCA 3′
Table 3 Primers used for RNA in vitro binding assays and
locked nucleic acid (LNA) sequences
RNA substrate Primer Sequence
Forward #4759 5′ TAA TAC GAC TCA CTA TAG GG AC
ATG AGG ATC ACC CAT GTG AAT TCG
AAT AGG CGT TAC TCG ACA 3′
Reverse #4761 5′ GGA TGC TTC CAG GGC 3′
LNA Specifity Sequence
αESEtat ESEtat 5′ TTCTTGCTCTCCTCTG 3′
αESE2/ESS2 ESE2/ESS2 5′ TCTAGTCTAGGATCTA 3′
Scrambled - 5′ GACGCGTCCTTACGCG 3′
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HEK 293T and HeLa cells were maintained in DMEM
(Invitrogen) supplemented with 10% fetal calf serum
(FCS) and 50 μg/ml of each penicillin and streptomycin
(P/S) (Invitrogen). Plasmid transfections were carried
out in six-well plates with 2.5×105 HEK293T or HeLa
cells per plate using TransIT®-LT1 reagent (Mirus Bio
LLC) following the manufacturer’s instructions. LNA co-
transfections were done in six-well plates with 2.5×105
HeLa cells per plate grown in Opti-MEM (Invitrogen)
supplemented with 5% FCS. 24 h later cells were trans-
fected with pNL4-3 alone or pNL4-3 together with the
respective LNA (80 nM) using Lipofectamine 2000 as
described previously [16].Infection experiments
Stocks of wild-type and mutant NL4-3 virus were pre-
pared and titers determined as described elsewhere [16].
5×105 Jurkat T-cells were infected with 10 ng of p24gag
of wild-type and mutant virus in serum-free RPMI
medium. 6 h later infected cells were washed in PBS
(Invitrogen) and resuspended in 10% FCS and 1% P/S-
containing RPMI medium. 6 days post infection cells
and supernatants were collected to obtain RNA and pro-
tein samples for further analyses.
RNA extraction, RT-PCR and Northern blot analyses
Total RNA samples were collected 48 h post transfection
or 6 days post infection. For RT-PCR analyses RNA was
reverse transcribed using Superscript III Reverse Tran-
scriptase (Invitrogen) and Oligo(dT) primer (Invitrogen).
For semi-quantitative analyses of viral tat mRNAs and vpr
mRNA splicing, cDNA was used in a PCR reaction with
primers #1544 (E1) and #3632 (E4) (see Table 2). For the
analysis of intronless 2 kb HIV-1 mRNAs, a PCR reaction
was carried out with forward primer #1544 (E1) and re-
verse primer #3392 (E7). Intron -containing 4 kb HIV-1
mRNAs were detected with primers #1544 (E1) and #640
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derived from central splice acceptor selection another
PCR reaction was performed with primers #1544 (E1) and
#3637 (E5). A separate PCR reaction with primer pair
#1224/#1225 detecting GH1-mRNA was carried out to
monitor for equal transfection efficiencies. All GH1-
mRNA RT-PCR reactions were performed at 26 cycles
within the linear range of amplification.
All primer sequences used for semi-quantitative RT-
PCR analyses are listed in Table 2. PCR products were
separated on 8% non-denaturing polyacrylamide gels and
stained with ethidium bromide for visualization. Real-time
PCR assays for the quantification of single mRNA species
were carried out with primer pair #3631/#3632 for Tat1-
mRNA and #3387/#3388 for overall viral mRNA levels.
For normalization, primers #5163 and #5164 were used
monitoring cellular GAPDH expression present in each
sample. Fluorescence emission was read by a Light Cycler
1.5 (Roche). Data are presented as the average of three
independently performed RT-PCR experiments.
For Northern blot analysis of viral mRNAs, total RNA
was separated on denaturating 1% agarose gels, capillary
blotted onto positively charged nylon membranes and
probed with an digoxigenin (DIG)-labeled HIV-1 exon 7
PCR product (#3387/#3388).
Antibodies
The following primary antibodies were used for immuno-
blot analysis: mouse antibody against α-actin (A2228) and
rabbit antibody against HA (H6908) were both obtained
from Sigma-Aldrich. Sheep antibody against HIV-1 p24 was
purchased from Biochrom AG. Rabbit antibodies directed
against viral Tat (ab43014) and SRSF2 (ab28428) were pro-
vided by Abcam. Mouse antibody against phosphorylated
SR proteins (1H4G7) was obtained from Invitrogen.
Rabbit antibody against MS2 was provided by Tetracore
(TC7004). For detection, we used a horseradish peroxidase
(HRP)-conjugated anti-mouse antibody (NA931) from
GE Healthcare, a HRP-conjugated anti-rabbit antibody
(A6154) from Sigma-Aldrich and a HRP-conjugated anti-
sheep antibody from Jackson Immunoresearch Laboratories
Inc. For immunofluorescence analysis we used an anti-HA
antibody (Sigma-Aldrich, clone HA-7) to detect the HA-
tagged SRSF6 variants and an Alexa Fluor® 488 conjugated
AffiniPure goat anti-mouse IgG (1:200; Jackson Immuno-
Research) as secondary antibody.
Protein analysis
Transfected cells were lysed in RIPA buffer (25 mM
Tris·HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium
deoxycholate, 0.1% SDS, protease inhibitor cocktail
(Roche)). Proteins were separated by SDS polyacrylamide
gel electrophoresis, transferred to nitrocellulose mem-
brane and subjected to immunoblotting procedure.Membranes were incubated with the respective primary
and secondary antibodies and developed with ECL chemi-
luminescence reagents (GE Healthcare).
Immobilization of RNA on agarose beads and RNA affinity
assays
For in vitro transcription of wild-type and mutant substrate
RNAs, DNA templates were amplified from respective pro-
viral plasmids with forward primer #4759 containing a T7
promoter sequence and a single copy of an MS2 RNA
binding site at the 5′-end and #4761 as a reverse primer
(see Table 3). RNA was synthesized using the RiboMax™
large scale RNA production system (P1300, Promega) ac-
cording to the manufacturer’s instructions. Substrate RNAs
were covalently coupled to adipidic acid dihydrazide-
Agarose beads as previously described [12,20,39]. Subse-
quently, immobilized RNAs were incubated in 30% HeLa
cell nuclear extract (Cilbiotech)/buffer D (20 mM HEPES-
KOH [pH 7.9], 5% glycerol, 0.1 M KCl, 0.2 mM EDTA,
0.5 mM DTT) for 20 min at 30°C. Recombinant MS2 coat
protein was added to nuclear extract dilutions to monitor
equal precipitation efficiencies. After washing off unspecifi-
cally bound proteins, remaining fraction on the RNAs was
eluted by addition of an equal volume of 2× protein sample
buffer and heating at 95°C for 10 min. Samples were then
resolved by SDS-PAGE and transferred to nitrocellulose
membranes for probing with specific antibodies.
Immunofluorescence analyses
HeLa cells were transiently transfected with plasmids ex-
pressing the HA-tagged SRSF6 variants (SRSF6-HA;
RRM1/H-HA; RRM1/L-HA and RRM1-HA). 24 hrs post
transfection cells were fixed with 4% paraformaldehyde
(wt/vol) in PBS (10 min, RT), permeabilized with 0.3%
Triton X-100 (vol/vol) in PBS (10 min, RT) and blocked
with 2% (vol/vol) normal goat serum (DaKoCytomation)
for 30 min. For staining of the overexpressed SRSF6
variants the cells were incubated with a monoclonal
mouse anti-HA antibody at a concentration of 1:750 di-
luted in PBS with 0.2% normal goat serum. After 1 h the
antibody-solution was removed, cells were washed three
times with PBS for 5 minutes and subsequently incubated
with Alexa Fluor® 488 conjugated AffiniPure goat anti-
mouse IgG diluted in PBS with 0.2% normal goat serum
for 45 min. This was followed by two times washing of the
cells with PBS, the staining of the nuclei with DAPI
(Invitrogen) (1:5000 in PBS) for 3 min and the fixing of
the cover slips on glass slides with FluoromountG (South-
ern Biotech). The localization of the SRSF6 variants was
then analyzed using a LSM780 confocal microscope
(Zeiss, Oberkochen, Germany). To avoid crosstalk in the
detection of the used fluorophores, multitracking scanning
mode was used. Image analyses and processing was per-
formed with ZEN (Zeiss).
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